Companies and Markets
Call us on +44 (0) 203 086 8600
Market Research A to Z | Company Profiles A to Z | RegisterRegister | Contact UsContact Us | Shopping Basket Shopping Basket
+44 (0) 203 086 8600 Call us on

Combination Devices - Application Landscape

3887.61

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

Corporate License

Corporate License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£3,887.61

Change Currency

GBP EURO USD
GBP EURO USD

Market

Healthcare and Medical

Report Type

Market Research

Country

Global

Published

22 June 2011

Number of Pages

68

Report Delivery

Email

Delivery Lead Time

1-3 hours, 24 hour max

Publisher

Frost and Sullivan

File Format

-

Report: Medical Device Application Market Landscape Influenced by the Adoption of Emerging Drug-Device Combinations

Minimally invasive combination drug-device approaches are emerging as viable treatment options that can extend survival, decrease organ toxicity, and improve the quality of life of patients with severe indications. Novel developments in technology and supporting clinical data have made a strong case for the adoption of the combination drug-device approach for pathology research. The rapid advances in image-guidance technologies have also made precise and effective application of combination drug-device approach a clinically feasible option. Drug delivery systems have always comprised a vast segment of biomaterials R&D, and this branch of technology development has got a boost from the demand for smart and biocompatible drug delivery devices. Despite its nascence, drug-device combination is demonstrating its efficiency in targeted drug delivery through the adoption of popular approaches involving nanotechnology, photodynamic therapy, and antimicrobial implants, apart from tablets and pills. Combination devices, with their unique construction and drug release profiles, have changed the way drugs are administered. A targeted approach enables the delivery of higher therapeutic dosages while minimizing adverse side effects. It offers greater control over toxicity and bioavailability of dose in addition to continuous therapeutic drug release over prolonged periods.

Through combination techniques, silica nanorattles as drug carriers of anti-tumor drug docetaxel can now be used for sustained and pH-sensitive drug release. Similarly, conventional polymers can be incorporated with nanoparticles to form nano composites for achieving targeted drug delivery. Among the diverse existing platforms, nano-biomaterials under investigation for cancer treatment have garnered significant attention due to their unique features. Drug delivery devices are inherently complex systems that require the integration of the drug substance, formulation, container closure, and the device for optimum product functionality. Nowadays, patient-driven delivery devices incorporating a biologics portfolio are emerging as better alternatives to single-entity devices for providing enhanced therapeutic advantages. The detection of cancer indications is one of the most important areas of pathology influenced by the integration of combination device. Cancer treatment needs to address the two formidable challenges of tumor heterogeneity and adaptive resistance. As a platform technology, the combination of multiple parameters has the remarkable ability to target tumor markers and deliver agents simultaneously for synergy in addressing the dual challenges of cancer heterogeneity and adaptive resistance.

Customer preference for miniaturized platforms is compelling combination device manufacturers to create implantable devices for diagnostic and therapeutic delivery at the micro to nano levels. As more companies begin to adopt the open innovation model for developing products, inventions will pick up pace steadily across combining drugs, devices, and biologics. To ensure the speed does not slacken, manufacturers have to guard against suboptimal drug products, as the wrong drug mixture can lead to harmful side effects. A poor choice of biomaterials can cause the coating to flake off or too much drug being deposited in the body. Technology developers are still unable to achieve the desired efficacy levels for the therapy sought. Further, they often lack the funds to take the product to the commercialization phase. Therefore, companies often license their products to a large device manufacturer or collaborate with a pharmaceutical company to get the product to the market. As combination devices is a relatively new concept within the medical devices sector, technology licensing, spin-off companies, and research groups are normally the prevailing model for commercialization, both for emerging companies as well as major participants.

Application Sectors

Expert analysts thoroughly examine the following market sectors in this research:

Diagnostic tools
Bacteriophages
Antibiotics

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

Corporate License

Corporate License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£3,887.61

Change Currency

GBP EURO USD

Change Currency

GBP
USD

Visitor Comments

All posts are pre-moderated and must obey the house rules.

Change Currency

GBP
USD

Use our research skills: Get free support

Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support

eBrandPromote: Get your brands ranked highly online

eBrandPromote: Let us promote your brand online through article writing, press release distribution, social media and search engine marketing services. Click here to download our eBrandPromote brochure.

Accessibility
Close

Contrast settings

Text size settings